Azuma, Junichi <br/><br/>
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.  [electronic resource] 

 -  European journal of clinical pharmacology  May 2013 
 - 1091-101 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-1041 
<br/><br/><label>Standard No.: </label>10.1007/s00228-012-1429-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Animals<br/>Antitubercular Agents--adverse effects<br/>Arylamine N-Acetyltransferase--genetics<br/>Asian People--genetics<br/>Chemical and Drug Induced Liver Injury--genetics<br/>Genetic Predisposition to Disease--genetics<br/>Genotype<br/>Humans<br/>Isoniazid--adverse effects<br/>Male<br/>Middle Aged<br/>Precision Medicine--methods<br/>Treatment Failure<br/>Tuberculosis--drug therapy